Overview
- Novo Nordisk confirmed Wegovy is now available in Argentine pharmacies by prescription and said patient support is in place while it negotiates reimbursement with prepagas and obras sociales.
- Retail listings show prices from about ARS 296,309 for starter doses to ARS 696,919 for the 2.4 mg monthly pack of four prefilled pens.
- The therapy is indicated for adults with obesity or overweight plus weight-related conditions, and for adolescents 12 and older weighing more than 60 kg, alongside diet and physical activity.
- Clinical studies reported an average weight reduction near 17%, with around one in three patients losing about 20%; separate data linked semaglutide to roughly 20% fewer major cardiovascular events and lower all-cause mortality.
- Health authorities and clinicians warn against aesthetic or unsupervised use, cite gastrointestinal side effects in roughly 10% of patients, and note weight regain is common after discontinuation.